Mucosal vaccination--an old but still vital strategy
- PMID: 23094329
Mucosal vaccination--an old but still vital strategy
Abstract
The basic premise of vaccinology is to achieve strong protective immunity against defined infectious agents by a vaccine mimicking the effects of natural primary exposure to a pathogen. Because an exposure of humans and animals to microbes occurs mostly through mucosal surfaces, targeting the mucosa seems a rational and efficient vaccination strategy. Many experimental and clinical data confirmed that mucosal immunization offers many advantages over widely used in human and veterinary medicine subcutaneous or intramuscular immunization. In the present article selected aspects regarding mucosal vaccination are discussed. The structure and function of mucosa-associated lymphoid tissue (MALT), comprised of four main mucosal compartments forming a structural and functional unity as well as pivotal cellular MALT components (dendritic and M cells) were briefly characterized. Particular attention was focused on the mode of simple but efficacious delivery of vaccine antigens to mucosal surfaces. A few trials to generate potential mucosal vaccines against toxoplasmosis introduced by nasal or oral routes to experimental animals are also presented.
Similar articles
-
[Mucosal immunity and vaccine development].Med Sci (Paris). 2007 Apr;23(4):371-8. doi: 10.1051/medsci/2007234371. Med Sci (Paris). 2007. PMID: 17433226 Review. French.
-
New insights in mucosal vaccine development.Vaccine. 2012 Jan 5;30(2):142-54. doi: 10.1016/j.vaccine.2011.11.003. Epub 2011 Nov 12. Vaccine. 2012. PMID: 22085556 Review.
-
[New routes of administration: epidermal, transcutaneous mucosal ways of vaccination].Med Sci (Paris). 2007 Apr;23(4):379-85. doi: 10.1051/medsci/2007234379. Med Sci (Paris). 2007. PMID: 17433227 Review. French.
-
B cell and T cell immunity in the female genital tract: potential of distinct mucosal routes of vaccination and role of tissue-associated dendritic cells and natural killer cells.Clin Microbiol Infect. 2012 Oct;18 Suppl 5:117-22. doi: 10.1111/j.1469-0691.2012.03995.x. Epub 2012 Aug 10. Clin Microbiol Infect. 2012. PMID: 22882377 Review.
-
Approaches to tuberculosis mucosal vaccine development using nanoparticles and microparticles: a review.J Biomed Nanotechnol. 2014 Sep;10(9):2295-316. J Biomed Nanotechnol. 2014. PMID: 25992458 Review.
Cited by
-
IL-22 deficiency increases CD4 T cell responses to mucosal immunization.Vaccine. 2018 Jun 14;36(25):3694-3700. doi: 10.1016/j.vaccine.2018.05.011. Epub 2018 May 5. Vaccine. 2018. PMID: 29739717 Free PMC article.
-
Challenges in mucosal HIV vaccine development: lessons from non-human primate models.Viruses. 2014 Aug 15;6(8):3129-58. doi: 10.3390/v6083129. Viruses. 2014. PMID: 25196380 Free PMC article. Review.
-
Respiratory nanoparticle-based vaccines and challenges associated with animal models and translation.J Control Release. 2015 Dec 10;219:622-631. doi: 10.1016/j.jconrel.2015.09.047. Epub 2015 Sep 26. J Control Release. 2015. PMID: 26410807 Free PMC article. Review.
-
Strategies to Develop a Mucosa-Targeting Vaccine against Emerging Infectious Diseases.Viruses. 2022 Mar 3;14(3):520. doi: 10.3390/v14030520. Viruses. 2022. PMID: 35336927 Free PMC article. Review.
-
Mucosal immunization with high-mobility group box 1 in chitosan enhances DNA vaccine-induced protection against coxsackievirus B3-induced myocarditis.Clin Vaccine Immunol. 2013 Nov;20(11):1743-51. doi: 10.1128/CVI.00466-13. Epub 2013 Sep 11. Clin Vaccine Immunol. 2013. PMID: 24027262 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical